References
- LeeAWMaBBNgWTManagement of nasopharyngeal carcinoma: current practice and future perspectiveJ Clin Oncol2015333356336426351355
- MaoYPXieFYLiuLZRe-evaluation of 6th edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement based on magnetic resonance imagingInt J Radiat Oncol Biol Phys2009731326133419153016
- ChenDSIrvingBAHodiFSMolecular pathways: next-generation immunotherapy–inhibiting programmed death-ligand 1 and programmed death-1Clin Cancer Res2012186580658723087408
- HsuCLeeSHEjadiSAntitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: interim results from a phase 1b studyAnn Oncol201526Suppl 9ix94
- ZhangJFangWQinTCo-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinomaMed Oncol20153238625702326
- FangWZhangJHongSEBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: implications for onco-targeted therapyOncotarget2014523121891220225361008
- ZhouYShiDMiaoJPD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA loadSci Rep201774362728256540
- LeeVHLoAWLeungCYCorrelation of PD-L1 expression of tumor cells with survival outcomes after radical intensity-modulated radiation therapy for non-metastatic nasopharyngeal carcinomaPLoS One2016116e015796927341634
- HsuMCHsiaoJRChangKCIncrease of programmed death-1- expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinomaMod Pathol201023101393140320657553
- ChanOSKowanetzMNgWTCharacterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancerOral Oncol201767526028351581
- ZhouYMiaoJWuHPD-1 and PD-L1 expression in 132 recurrent nasopharyngeal carcinoma: the correlation with anemia and outcomesOncotarget2017831512105122328881642
- JinTQinWFJiangFInterim analysis of a prospective randomized non-inferiority trial of cisplatin and fluorouracil induction chemotherapy with or without docetaxel in nasopharyngeal carcinomaOncotarget Epub2016728
- HutarewGPD-L1 testing, fit for routine evaluation? From a pathologist’s point of viewMemo20169420120628058063
- TengMWNgiowSFRibasAClassifying cancers based on T-cell infiltration and PD-L1Cancer Res201575112139214525977340
- FehrenbacherLSpiraABallingerMAtezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, openlabel, phase 2 randomised controlled trialLancet20163871837184626970723
- ScheelAHDietelMHeukampLCHarmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomasMod Pathol201629101165117227389313
- RatcliffeMJSharpeAMidhaAAgreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cut-offs in non-small cell lung cancerClin Cancer Res201723CCR-1116CCR-2375